Navigation Links
American Oriental Bioengineering Reports First Quarter 2009 Financial Results

NEW YORK, May 11 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products in China, today announced financial results for the first quarter ended March 31, 2009.

Financial Results

Revenue in the first quarter of 2009 increased 18.9% year over year to $46.1 million from $38.8 million, reflecting continued demand for the Company's core pharmaceutical and nutraceutical products. Revenue from pharmaceutical products increased 8.9% to $34.7 million from $31.9 million in the prior year's first quarter. Prescription pharmaceutical products revenue increased 14.5% to $16.2 million during the first quarter of 2009, reflecting prescription formulation Jinji and CCXA products, which offset declines in Shuanghuanglian Injection Powder ("SHL"). OTC pharmaceutical products generated $18.5 million in revenue during the first quarter of 2009, roughly flat to the prior year period, reflecting continued demand for Boke nasal spray and Jinji Yimucao products and a shift of Jinji Capsule products from OTC to prescription sales. Nutraceutical products generated revenue of approximately $8.9 million in the first quarter of 2009, up 29.0% from the prior year period, reflecting continued demand for peptide products and an expanded distribution network versus the prior year's first quarter. The Company generated $2.5 million in distribution revenue in the first quarter of 2009 from Nuo Hua's majority owned subsidiary.

Gross profit in the first quarter of 2009 increased 8.1% to $28.4 million from $26.3 million in the first quarter of 2008. Gross margin was 61.7%, compared with 67.8% in the prior year period, reflecting lower margin distribution revenue and CCXA's generic product sales.

Operating income in the first quarter was $11.2 million compared with $12.0 million in the prior year period, reflecting a 20.2% increase in operating expenses to $17.2 million in the first quarter of 2009 from $14.3 million in the prior year period. General and administration expenses as well as selling and marketing expenses increased 9.3% to $9.8 million from $8.9 million in the prior year period. The increase primarily reflects marketing and promotional initiatives related to Jinji and Boke products. Advertising expense increased 26.7% to $5.6 million in the first quarter of 2009, compared to $4.4 million in the prior year period.

Net income for the first quarter of 2009 was $7.9 million, compared to $9.4 million in the prior year period. Excluding the $1.7 million of interest expense related to the Company's outstanding convertible notes in the first quarter of 2009, which did not occur in the first quarter of 2008, net income performance was roughly flat on a year over year basis. Net income per diluted share was $0.11 in the first quarter of 2009 compared to $0.12 per diluted share in the first quarter of 2008.

As of March 31, 2009, the Company had $73.9 million in cash and generated approximately $3.6 million of operating cashflow during the quarter.

Mr. Tony Liu, Chairman and Chief Executive Officer of American Oriental Bioengineering, commented, "We are pleased with our first quarter performance and have met our key near-term objective to foster a dynamic business model that is diversified across prescription, OTC and nutraceutical products. Notably, our distribution business began to strengthen overall performance this quarter, contributing to net income as anticipated, and enlarging our distribution reach, particularly for our prescription pharmaceutical products. We are more flexible today than we were one year ago and, because of this, we can quickly adapt to change and capitalize on new opportunities despite the uncertain regulatory environment. Our marketing capabilities, extensive distribution platform, compelling product portfolio and ongoing rural expansion offset anticipated challenges in SHL sales during the first quarter of 2009 and we remain focused on becoming a top five pharmaceutical company in China."

Conference Call

The Company will hold a conference call at 8:00 am ET on May 11, 2009 to discuss first quarter 2009 results. Listeners may access the call by dialing 1-866-798-2884 or 1-617-614-6207 for international callers, access code: 34266051. A webcast will also be available through AOBO's website at . A replay of the call will be available through May 18, 2009. Listeners may access the replay by dialing 1-888-286-8010 or 1-617-801-6888 for international callers, access code: 57318398.

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. is a China-based pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products.

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended December 31, 2008, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.


                                                    THREE MONTHS ENDED
                                                         March 31
                                                   2009              2008
    REVENUES                                   $46,077,190       $38,768,598
    COST OF GOODS SOLD                          17,660,338        12,477,636

    GROSS PROFIT                                28,416,852        26,290,962

    Selling and marketing                        5,211,502         5,029,708
    Advertising                                  5,567,357         4,394,341
    General and administrative                   4,565,643         3,912,683
    Depreciation and amortization                1,858,915           977,210

    Total operating expenses                    17,203,417        14,313,942

    INCOME FROM OPERATIONS                      11,213,435        11,977,020

     UNCONSOLIDATED ENTITIES                       437,794                --
    INTEREST INCOME (EXPENSE), NET              (1,579,269)           16,847
    OTHER (EXPENSE), NET                           (98,609)         (101,790)

    INCOME BEFORE INCOME TAXES                   9,973,351        11,892,077
    INCOME TAXES                                 2,103,299         2,469,948

    NET INCOME                                   7,870,052         9,422,129
     CONTROLLING INTEREST                           (3,551)               --
     CONTROLLING INTEREST                        7,866,501         9,422,129

    Foreign currency translation gain,
     net of tax                                    378,466         6,934,434
     TAX                                           378,466         6,934,434

    COMPREHENSIVE INCOME                        $8,244,967       $16,356,563

      BASIC                                          $0.11             $0.12
      DILUTED                                        $0.11             $0.12
      BASIC                                     74,538,593     78,191,242.00
      DILUTED                                   86,917,603     78,192,795.00


                                               March 31,       DECEMBER 31,
                                                  2009             2008
    Cash and cash equivalents                 $73,899,602      $70,636,510
    Accounts receivable, net of reserve
     of $130,631 and $226,330 at March 31,
     2009 and December 31, 2008,
     respectively                              31,812,778       36,982,167
    Inventories, net of provision for
     slow moving inventories                   17,954,075       13,042,123
    Advances to suppliers                       2,241,176        3,593,979
    Notes receivable                            1,039,914          708,076
    Refundable deposit                          6,397,106        6,396,996

    Tax refund claims                             823,737               --
    Deferred tax assets                           456,444          347,216
    Other current assets                          863,554          744,903
            Total Current Assets              135,488,386      132,451,970

    Plant and equipment, net                   97,192,300       98,154,443
    Land use rights, net                      148,319,092      148,988,870
    Deposit for long-term assets                6,355,148        6,347,174
    Construction in progress                   25,675,899       25,385,835
    Deferred tax assets                         1,322,194        1,313,832
    Other intangible assets, net               22,426,393       23,690,440
    Goodwill                                   28,543,226       28,543,226
    Investments in and advances to
     equity investments                        55,554,438       54,963,064
    Unamortized financing costs                 3,983,911        4,215,983
           Total Long-Term Assets             389,372,601      391,602,867

                TOTAL ASSETS                 $524,860,987     $524,054,837


                                              DECEMBER 31,     DECEMBER 31,
                                                  2008             2007
    Accounts payable                          $10,355,431      $12,287,887
    Notes payables                              3,277,285        3,262,877
    Other payables and accrued expenses        13,578,351       19,766,652
    Taxes payable                                      --          420,671
    Short-term bank loans                       7,441,276        7,140,148
    Current portion of long-term bank
     loans                                         59,022           58,659
    Other liabilities                           2,738,113        2,253,440
    Deferred tax liability                        999,454          846,026
         Total Current Liabilities             38,448,932       46,036,360

    Long-term bank loans                          789,579          804,521
    Long-term notes payable                            --          269,908
    Deferred tax liabilities                   16,102,048       16,083,768
    Convertible Note                          115,000,000      115,000,000
        Total Long-Term Liabilities           131,891,627      132,158,197
             TOTAL LIABILITIES                170,340,559      178,194,557

    Preferred stock, $0.001 par value;
     2,000,000 shares authorized;
     1,000,000 shares issued and
     outstanding at March 31, 2009 and
     December 31, 2008, respectively                1,000            1,000
    Common stock, $0.001 par value;
     150,000,000 shares authorized;
     78,291,735 and 78,249,264 shares
     issued and outstanding at March
     31, 2009 and December 31, 2008,
     respectively                                  78,292           78,249
    Common stock to be issued                     177,000          376,335
    Prepaid forward repurchase contract       (29,998,616)     (29,998,616)
    Additional paid-in capital                196,352,466      195,741,544
    Retained earnings (the restricted
     portion of retained earnings is
     $29,532,699 at March 31, 2009 and
     December 31, 2008)                       157,790,182      149,923,681
    Accumulated other comprehensive
     income                                    29,464,472       29,086,006
         Total Shareholders' Equity           353,864,796      345,208,199
    NONCONTROLLING INTEREST                       655,632          652,081
                TOTAL EQUITY                  354,520,428      345,860,280
     EQUITY                                  $524,860,987     $524,054,837

SOURCE American Oriental Bioengineering, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. SportCoatings; The North American Booster Club Association (NABCA); the Coatings Specialist Group New Booster Program Goes High Tech With Invisible Antimicrobial Defense
3. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
4. American Oriental Bioengineering Announces Participation in September Investor Conferences
5. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
6. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
7. Tips from the Journals of the American Society for Microbiology
8. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
9. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers
10. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
11. AUDIO from Medialink and Pfizer: Hispanic Heritage Month Reminds Us Increasing Numbers of Hispanic-Americans Do Not Have Health Insurance
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive ... a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... business process optimization firm for the life sciences and healthcare industries, announces a ... in San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” ...
Breaking Biology Technology:
(Date:10/4/2017)... 4, 2017  GCE Solutions, a global clinical research organization (CRO), ... anonymization solution on October 4, 2017. Shadow is designed to assist ... with policy 0070 of the European Medicines Agency (EMA) in meeting ... ... ...
(Date:6/23/2017)... ARMONK, N.Y. and ITHACA, N.Y. ... IBM ) and Cornell University, a leader in dairy ... combined with bioinformatics designed to help reduce the chances ... breaches. With the onset of this dairy project, Cornell ... the Consortium for Sequencing the Food Supply Chain, a ...
(Date:5/6/2017)... RAM Group , Singaporean based ... in biometric authentication based on a novel  ... to perform biometric authentication. These new sensors are based on ... Ram Group and its partners. This sensor will have ... and security. Ram Group is a next generation ...
Breaking Biology News(10 mins):